Treatment strategies for atrial fibrillation

The American Journal of Medicine
F Jung, J P DiMarco

Abstract

Atrial fibrillation is the most common arrhythmia observed in clinical practice, occurring in 0.4% of the general population and in up to 4% of people greater than 60 years old. It is often associated with other cardiovascular disorders, such as hypertension, coronary artery disease, or cardiomyopathy. Critical evaluation and management of patients with atrial fibrillation requires knowledge of etiology, prognosis, and treatment options of this arrhythmia. On initial presentation, emergency electrical cardioversion should be performed if the patient is hemodynamically unstable. If the patient is stable, initial rate control is recommended, using atrioventricular nodal blocking agents. Further treatment mainly depends upon the duration of the episode. Patients who are in atrial fibrillation <48 hours can be safely cardioverted. Patients who are in atrial fibrillation for >48 hours are commonly anticoagulated for 3 to 4 weeks before and after cardioversion because of the risk of thromboembolism formation in the left atrial appendage. An alternate strategy, which is especially attractive when immediate cardioversion is desired, is transesophageal echocardiography to exclude left atrial thrombus followed by prompt cardioversion. Af...Continue Reading

References

Aug 20, 1992·The American Journal of Cardiology·K D DonovanG M Clarke
May 7, 1992·The New England Journal of Medicine·E L Pritchett
Jun 15, 1992·Annals of Internal Medicine·H R MiddlekauffW G Stevenson
Jul 15, 1992·Annals of Internal Medicine·R H Falk
Feb 1, 1990·Pacing and Clinical Electrophysiology : PACE·R CorbelliB L Wilkoff
Dec 1, 1990·Pacing and Clinical Electrophysiology : PACE·R ZaniniL Dei Cas
Dec 1, 1990·Pacing and Clinical Electrophysiology : PACE·W GrimmK Kochsiek
Aug 1, 1991·Stroke; a Journal of Cerebral Circulation·P A WolfW B Kannel
May 1, 1991·The American Journal of Cardiology·E L Pritchett, W E Wilkinson
Jul 1, 1991·Postgraduate Medical Journal·B CarrK S Channer
Nov 29, 1990·The New England Journal of Medicine·UNKNOWN Boston Area Anticoagulation Trial for Atrial Fibrillation InvestigatorsJ Philip Kistler
Jan 2, 1990·The American Journal of Cardiology·A J Camm, V Paul
Jan 1, 1989·Journal of Cardiovascular Pharmacology·L M van WijkK I Lie
Dec 1, 1989·The American Journal of Cardiology·J M FeuerJ C Messenger
Aug 25, 1988·The American Journal of Cardiology·J L AndersonP A Fredell
Oct 1, 1988·Journal of the American College of Cardiology·E M AntmanP L Friedman
Sep 1, 1986·The American Journal of Cardiology·A BorgeatU Sigwart
Sep 1, 1986·Journal of the American College of Cardiology·J MorganrothG D Gentzkow
Jan 1, 1986·Journal of the American College of Cardiology·W AschenbergW Bleifeld

❮ Previous
Next ❯

Citations

Jul 4, 2003·Postgraduate Medical Journal·A Wakai, J O O'Neill
Apr 26, 2003·International Journal of Cardiology·Carlo Pappone, Salvatore Rosanio
Sep 20, 2005·International Journal of Cardiology·Panagiotis KorantzopoulosKonstantinos Siogas
Sep 25, 2002·Clinical Cardiology·Mithilesh Kumar DasMajesh Makan
Jul 17, 2001·The Australian & New Zealand Journal of Obstetrics & Gynaecology·O BrownJ Palmer
Aug 24, 2012·Journal of Cardiovascular Electrophysiology·Youhua ZhangTodor N Mazgalev
Dec 15, 2005·Heart, Lung & Circulation·Donald B Doty
Oct 4, 2005·Emergency Medicine Clinics of North America·Arun V RaghavanThomas D Meloy
Mar 5, 2004·Cardiology Clinics·Robert A VerNooy, J Paul Mounsey
Mar 26, 1999·Journal of the American College of Cardiology·G E KochiadakisP E Vardas
Dec 8, 2004·Journal of the American College of Cardiology·Cornelis S van der HooftBruno H Ch Stricker
Jul 24, 2003·Journal of the American College of Cardiology·Brian D Hoit
Mar 22, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·J GalperínUNKNOWN GEFCA Investigators-GEMA Group, Buenos Aires, Argentina
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·T A Burkart, A B Curtis
May 14, 2003·Circulation·Ravi KanagalaVirend K Somers
Sep 4, 2004·PharmacoEconomics·M P TengD P Melby
Mar 8, 2000·The American Journal of Nursing·R S Bubien
Aug 30, 2012·Journal of Cardiovascular Medicine·Wei WangXi-Li Yang
Jun 6, 2002·Clinical Obstetrics and Gynecology·Barry A Harrison, Christopher M Burkle
Mar 19, 2002·BMC Cardiovascular Disorders·Ana RuigómezLuis Alberto García Rodríguez
Sep 15, 2001·American Journal of Physiology. Heart and Circulatory Physiology·D W WallickT N Mazgalev
Feb 9, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Youhua ZhangTodor N Mazgalev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.